IndexIQ Advisors LLC Takes Position in Intersect ENT, Inc. (NASDAQ:XENT)

IndexIQ Advisors LLC acquired a new stake in Intersect ENT, Inc. (NASDAQ:XENT) during the third quarter, HoldingsChannel.com reports. The fund acquired 94,707 shares of the medical equipment provider’s stock, valued at approximately $2,576,000.

Several other large investors have also recently bought and sold shares of the company. Moors & Cabot Inc. bought a new position in Intersect ENT during the third quarter worth $269,000. Lumature Wealth Partners LLC bought a new position in Intersect ENT during the third quarter worth $106,000. Sphinx Trading LP bought a new position in Intersect ENT during the third quarter worth $190,000. Royal Bank of Canada boosted its stake in Intersect ENT by 6.8% during the second quarter. Royal Bank of Canada now owns 8,780 shares of the medical equipment provider’s stock worth $150,000 after acquiring an additional 558 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY boosted its stake in Intersect ENT by 119,788.9% during the second quarter. Metropolitan Life Insurance Co NY now owns 10,790 shares of the medical equipment provider’s stock worth $184,000 after acquiring an additional 10,781 shares in the last quarter. 92.85% of the stock is currently owned by institutional investors.

Shares of NASDAQ XENT opened at $27.23 on Friday. Intersect ENT, Inc. has a 12-month low of $15.92 and a 12-month high of $28.17. The company’s fifty day simple moving average is $27.14 and its 200 day simple moving average is $25.71. The company has a debt-to-equity ratio of 6.89, a current ratio of 2.36 and a quick ratio of 1.97.

Intersect ENT (NASDAQ:XENT) last released its quarterly earnings data on Tuesday, November 2nd. The medical equipment provider reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.06). Intersect ENT had a negative return on equity of 151.36% and a negative net margin of 85.02%. The business had revenue of $24.40 million for the quarter, compared to analyst estimates of $29.63 million. As a group, sell-side analysts forecast that Intersect ENT, Inc. will post -1.78 EPS for the current fiscal year.

Intersect ENT Profile

Intersect ENT, Inc is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps.

Recommended Story: How to invest in a bear market

Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT, Inc. (NASDAQ:XENT).

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.